Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy
- 28 February 2007
- journal article
- Published by Elsevier BV in Experimental Neurology
- Vol. 203 (2), 293-301
- https://doi.org/10.1016/j.expneurol.2006.09.028
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Institute on Aging
This publication has 26 references indexed in Scilit:
- New Therapeutic Strategies and Drug Candidates for Neurodegenerative Diseases: p53 and TNF‐α Inhibitors, and GLP‐1 Receptor AgonistsAnnals of the New York Academy of Sciences, 2004
- Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathyExperimental Neurology, 2004
- Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies)Muscle & Nerve, 2004
- The glucagon-like peptides: a double-edged therapeutic sword?Trends in Pharmacological Sciences, 2003
- Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and ironJournal of Neuroscience Research, 2003
- Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4Journal of Pharmacology and Experimental Therapeutics, 2002
- Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.JCI Insight, 1997
- A role for glucagon-like peptide-1 in the central regulation of feedingNature, 1996
- Distribution of GLP‐1 Binding Sites in the Rat Brain: Evidence that Exendin‐4 is a Ligand of Brain GLP‐1 Binding SitesEuropean Journal of Neuroscience, 1995
- Pyridoxine neuropathy: Correlation of functional tests and neuropathology in beagle dogs treated with large doses of vitamin B6Inflammation Research, 1982